XSHG
600422
Market cap925mUSD
Oct 09, Last price
8.36CNY
1D
2.20%
1Q
0.97%
Jan 2017
-38.12%
IPO
152.57%
Name
KPC Pharmaceuticals Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
KPC Pharmaceuticals, Inc. operates as a pharmaceutical enterprise, with its operations spanning drug research and development, manufacturing, marketing, and wholesale distribution. The company serves both domestic markets within the People's Republic of China and international clientele. Its portfolio prominently features botanical drugs, including artemether, panax notoginseng, and gastrodine series medications. These, along with various Chinese and ethnic remedies—marketed under brand names such as Luotai, Tianxuanqing, Artemedine, Artem, and Arco—are deployed in the treatment of conditions affecting the cardiovascular and cerebrovascular systems, neurological disorders, and malaria. Beyond its herbal focus, KPC Pharmaceuticals supplies a broad range of healthcare products. These include Dai ethnic preparations, antibiotics, raw chemical materials, prepared chemical pharmaceuticals, traditional Chinese medicinal ingredients, biologicals, biochemical agents, and nutritional supplements. Specific offerings encompass Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, Ribavirin spray, glycyrrhizic acid, and the long-acting hypoglycemic GLP-1. Additionally, the company distributes artemisinin-based antimalarials, various generic medications, and medical devices. Established in 1951, the firm was initially known as Kunming Pharmaceutical Corporation before adopting its current name, KPC Pharmaceuticals, Inc., in April 2015. Its corporate headquarters are located in Kunming, situated in the People's Republic of China.
Key people
Chairman of the Board · since 2025
Zhiqiang Sun
Chief Financial Officer, Finance Director · since 2023
Li Meng
Executive Vice President · since 2018
Junfeng Liu
Senior Vice President · since 2017
Tong Gao
Vice President · since 2024
Ming He
Vice President · since 2025
Lichun Li
Vice President · since 2025
Cheng Sun
Vice President · since 2024
Kai Xi
Vice President · since 2023
Mengxun Zhang
Vice President, General Counsel, Secretary of the Board · since 2024
Ting Guo
Director · since 2023
Zheng Liang
Director · since 2023
Director · since 2025
Director · since 2025
Vice Chairman of the Board · since 2026
Director · since 2025
Director · since 2023
Kan Ding
Independent Director · since 2025
Independent Director · since 2025
Independent Director · since 2021
Headquarters & legal address
云南省昆明市高新技术产业开发区科医路166号
昆明市, YN 100000
CN
昆明市, YN 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2021‑00 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||